Organon & (OGN) Fundamentals 2026 — P/E 14.2x, Revenue Analysis | SniperIQ
Organon & (OGN) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
Organon & (OGN) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
Organon & (OGN) has a market capitalization of approximately
Organon &'s trailing twelve-month P/E ratio is 14.2x, with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Organon & runs a net profit margin of 4.0%, a gross margin of 53.1%, and an operating margin of 19.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Organon & reported revenue of $6.2B for fiscal year 2025, with net income of
Organon & offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Organon & carries a debt-to-equity ratio of 9.49x and a current ratio of 1.97x, with a market beta of 1.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Organon & (OGN) the key facts are: market cap
Get Organon &'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.